transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Liver transplantation with deceased ABO-incompatible donors is life-saving but associated with increased risk of rejection and post-transplant complications

Författare och institution:
T. Thorsen (-); U. S. Dahlgren (-); E. M. Aandahl (-); K. Grzyb (-); T. H. Karlsen (-); K. M. Boberg (-); Lennart Rydberg (Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin); C. Naper (-); A. Foss (-); William Bennet (Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi)
Publicerad i:
Transplant International, 28 ( 7 ) s. 800-812
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
ABO-incompatible (ABOi) liver transplantation (LT) with deceased donor organs is performed occasionally when no ABO-compatible (ABOc) graft is available. From 1996 to 2011, 61 ABOi LTs were performed in Oslo and Gothenburg. Median patient age was 51years (range 13-75); 33 patients were transplanted on urgent indications, 13 had malignancy-related indications, and eight received ABOi grafts for urgent retransplantations. Median donor age was 55years (range 10-86). Forty-four patients received standard triple immunosuppression with steroids, tacrolimus, and mycophenolate mofetil, and forty-four patients received induction with IL-2 antagonist or anti-CD20 antibody. Median follow-up time was 29months (range 0-200). The 1-, 3-, 5-, and 10-year Kaplan-Meier estimates of patient survival (PS) and graft survival (GS) were 85/71%, 79/57%, 75/55%, and 59/51%, respectively, compared to 90/87%, 84/79%, 79/73%, and 65/60% for all other LT recipients in the same period. The 1-, 3-, 5-, and 10-year GS for A(2) grafts were 81%, 67%, 62%, and 57%, respectively. In conclusion, ABOi LT performed with non-A(2) grafts is associated with inferior graft survival and increased risk of rejection, vascular and biliary complications. ABOi LT with A(2) grafts is associated with acceptable graft survival and can be used safely in urgent cases.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
ABO, deceased, donor, incompatible, liver, subgroup A(2), transplantation, ANTIGEN-SPECIFIC IMMUNOADSORPTION, LIVING-DONOR, HLA ANTIBODIES, FAILURE, RITUXIMAB, MANAGEMENT, RECIPIENTS, A(2), Surgery, Transplantation
Postens nummer:
Posten skapad:
2015-07-10 11:02

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007